GRANISETRON

Granisetron Adverse Events Reported to the FDA Over Time

How are Granisetron adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Granisetron, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Granisetron is flagged as the suspect drug causing the adverse event.

Most Common Granisetron Adverse Events Reported to the FDA

What are the most common Granisetron adverse events reported to the FDA?

Fatigue	100 (3.26%)
Nausea	90 (2.94%)
Dyspnoea	87 (2.84%)
Vomiting	84 (2.74%)
Chest Discomfort	54 (1.76%)
Diarrhoea	54 (1.76%)
Malaise	44 (1.44%)
Rash	40 (1.31%)
Drug Interaction	37 (1.21%)
Chest Pain	36 (1.17%)
Convulsion	34 (1.11%)
	Show More
Hypotension	34 (1.11%)
Abdominal Pain	32 (1.04%)
Anaphylactic Shock	32 (1.04%)
Neutrophil Count Decreased	31 (1.01%)
Pyrexia	29 (.95%)
Headache	28 (.91%)
Pulmonary Artery Thrombosis	28 (.91%)
Decreased Appetite	27 (.88%)
Aspartate Aminotransferase Increase...	26 (.85%)
Stomatitis	26 (.85%)
Tachycardia	26 (.85%)
Alopecia	25 (.82%)
Constipation	25 (.82%)
Dehydration	25 (.82%)
Febrile Neutropenia	24 (.78%)
Hypertension	24 (.78%)
Chills	22 (.72%)
Cardio-respiratory Arrest	21 (.69%)
Death	20 (.65%)
Hyperhidrosis	20 (.65%)
Shock	20 (.65%)
General Physical Health Deteriorati...	19 (.62%)
Alanine Aminotransferase Increased	18 (.59%)
Gamma-glutamyltransferase Increased	18 (.59%)
Palmar-plantar Erythrodysaesthesia ...	18 (.59%)
Pruritus	18 (.59%)
Erythema	17 (.55%)
Dyskinesia	15 (.49%)
Cyanosis	14 (.46%)
Flushing	14 (.46%)
Haematoma	14 (.46%)
Injection Site Extravasation	14 (.46%)
International Normalised Ratio Incr...	14 (.46%)
Renal Failure Acute	14 (.46%)
Bradycardia	13 (.42%)
Contusion	13 (.42%)
Depressed Level Of Consciousness	13 (.42%)
Lymphopenia	13 (.42%)
Musculoskeletal Stiffness	13 (.42%)
Respiratory Depth Decreased	13 (.42%)
Thrombocytopenia	13 (.42%)
Abdominal Pain Upper	12 (.39%)
Blood Pressure Decreased	12 (.39%)
Cardiac Arrest	12 (.39%)
Myocardial Infarction	12 (.39%)
Neutropenia	12 (.39%)
Overdose	12 (.39%)
Swelling	12 (.39%)
Weight Decreased	12 (.39%)
Dizziness	11 (.36%)
Drug Ineffective	11 (.36%)
Hypersensitivity	11 (.36%)
Hyponatraemia	11 (.36%)
Inappropriate Antidiuretic Hormone ...	11 (.36%)
Muscle Spasms	11 (.36%)
Skin Exfoliation	11 (.36%)
Asthenia	10 (.33%)
Haemoglobin Decreased	10 (.33%)
Insomnia	10 (.33%)
Pain	10 (.33%)
Photosensitivity Reaction	10 (.33%)
Platelet Count Decreased	10 (.33%)
Somnolence	10 (.33%)
White Blood Cell Count Decreased	10 (.33%)
Anorexia	9 (.29%)
Atrial Fibrillation	9 (.29%)
Confusional State	9 (.29%)
Dystonia	9 (.29%)
Ileus	9 (.29%)
Loss Of Consciousness	9 (.29%)
Paraesthesia	9 (.29%)
Pneumonia Fungal	9 (.29%)
Pulmonary Oedema	9 (.29%)
Purpura	9 (.29%)
Tremor	9 (.29%)
Acute Generalised Exanthematous Pus...	8 (.26%)
Arthralgia	8 (.26%)
Dysphagia	8 (.26%)
Hallucination	8 (.26%)
Hepatitis Cholestatic	8 (.26%)
Hiccups	8 (.26%)
Hypoaesthesia	8 (.26%)
Intestinal Obstruction	8 (.26%)
Myalgia	8 (.26%)
Pain In Extremity	8 (.26%)
Renal Impairment	8 (.26%)
Sepsis	8 (.26%)
Skin Oedema	8 (.26%)
Swollen Tongue	8 (.26%)
Syncope	8 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Granisetron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Granisetron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Granisetron

What are the most common Granisetron adverse events reported to the FDA?

Gastrointestinal Signs	239 (7.8%)
Respiratory	167 (5.45%)
Epidermal And Dermal Conditions	136 (4.44%)
Neurological	99 (3.23%)
Cardiac Arrhythmias	96 (3.13%)
Gastrointestinal Motility And Defec...	92 (3%)
Hematology Investigations	90 (2.94%)
Hepatobiliary	72 (2.35%)
Infections - Pathogen Unspecified	69 (2.25%)
Skin Appendage Conditions	60 (1.96%)
Decreased And Nonspecific Blood Pre...	58 (1.89%)
	Show More
White Blood Cell	57 (1.86%)
Therapeutic And Nontherapeutic Effe...	56 (1.83%)
Allergic Conditions	55 (1.8%)
Electrolyte And Fluid Balance Condi...	48 (1.57%)
Seizures	46 (1.5%)
Cardiac And Vascular Investigations	45 (1.47%)
Hepatic And Hepatobiliary	42 (1.37%)
Movement Disorders	40 (1.31%)
Muscle	40 (1.31%)
Appetite And General Nutritional	37 (1.21%)
Musculoskeletal And Connective Tiss...	36 (1.17%)
Oral Soft Tissue Conditions	32 (1.04%)
Body Temperature Conditions	31 (1.01%)
Pulmonary Vascular	31 (1.01%)
Renal Disorders	31 (1.01%)
Headaches	30 (.98%)
Administration Site Reactions	29 (.95%)
Fungal Infectious	28 (.91%)
Gastrointestinal Stenosis And Obstr...	28 (.91%)
Urinary Tract Signs	26 (.85%)
Vascular	26 (.85%)
Vascular Hypertensive	26 (.85%)
Skin Vascular Abnormalities	25 (.82%)
Coronary Artery	24 (.78%)
Central Nervous System Vascular	21 (.69%)
Fatal Outcomes	21 (.69%)
Injuries	21 (.69%)
Physical Examination Topics	20 (.65%)
Joint	19 (.62%)
Lower Respiratory Tract Disorders	19 (.62%)
Cardiac Disorder Signs	18 (.59%)
Skin And Subcutaneous Tissue	18 (.59%)
Bone And Joint Injuries	17 (.55%)
Medication Errors	16 (.52%)
Platelet	16 (.52%)
Vascular Hemorrhagic	16 (.52%)
Bacterial Infectious	14 (.46%)
Deliria	13 (.42%)
Gastrointestinal Ulceration And Per...	13 (.42%)
Anemias Nonhemolytic And Marrow Dep...	12 (.39%)
Ocular Neuromuscular	12 (.39%)
Embolism And Thrombosis	11 (.36%)
Gastrointestinal Inflammatory Condi...	11 (.36%)
Hypothalamus And Pituitary Gland	11 (.36%)
Inner Ear And Viiith Cranial Nerve	11 (.36%)
Sleep Disorders	11 (.36%)
Tongue Conditions	11 (.36%)
Toxicology And Therapeutic Drug Mon...	11 (.36%)
Leukemias	10 (.33%)
Bronchial Disorders	9 (.29%)
Gastrointestinal Hemorrhages	9 (.29%)
Bone Disorders	8 (.26%)
Dental And Gingival Conditions	8 (.26%)
Disturbances In Thinking	8 (.26%)
Metabolic, Nutritional And Blood Ga...	8 (.26%)
Respiratory And Mediastinal Neoplas...	8 (.26%)
Renal And Urinary Tract Investigati...	7 (.23%)
Upper Respiratory Tract Disorders	7 (.23%)
Angiedema And Urticaria	6 (.2%)
Anxiety Disorders	6 (.2%)
Mental Impairment	6 (.2%)
Peripheral Neuropathies	6 (.2%)
Pleural	6 (.2%)
Procedural And Device Related Injur...	6 (.2%)
Therapeutic Procedures And Supporti...	6 (.2%)
Water, Electrolyte And Mineral	6 (.2%)
Chemical Injury And Poisoning	5 (.16%)
Coagulopathies And Bleeding Diathes...	5 (.16%)
Enzyme	5 (.16%)
Hematological	5 (.16%)
Miscellaneous And Site Unspecified ...	5 (.16%)
Neuromuscular	5 (.16%)
Bone, Calcium, Magnesium And Phosph...	4 (.13%)
Encephalopathies	4 (.13%)
Glucose Metabolism Disorders	4 (.13%)
Hemolyses And Related Conditions	4 (.13%)
Lipid Analyses	4 (.13%)
Male Reproductive Tract Infections ...	4 (.13%)
Metastases	4 (.13%)
Ocular Infections, Irritations And ...	4 (.13%)
Pericardial	4 (.13%)
Protein And Chemistry Analyses	4 (.13%)
Sexual Dysfunctions, Disturbances A...	4 (.13%)
Viral Infectious	4 (.13%)
Vision	4 (.13%)
Arteriosclerosis, Stenosis, Vascula...	3 (.1%)
Changes In Physical Activity	3 (.1%)
Cranial Nerve Disorders	3 (.1%)
Neurological Disorders Of The Eye	3 (.1%)
Ocular Sensory Symptoms	3 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Granisetron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Granisetron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.